Back to Search Start Over

Discovery of oral-available resveratrol-caffeic acid based hybrids inhibiting acetylated and phosphorylated STAT3 protein.

Authors :
Li, Shanshan
Zhang, Wenda
Yang, Yanwei
Ma, Ting
Guo, Jianpeng
Wang, Shanshan
Yu, Wenying
Kong, Lingyi
Source :
European Journal of Medicinal Chemistry. Nov2016, Vol. 124, p1006-1018. 13p.
Publication Year :
2016

Abstract

Constitutive activation of STAT3 has been found in a wide variety of cancers and demonstrated as a very attractive therapeutic target. Disrupting both acetylation and phosphorylation of STAT3 protein was hypothesized to greatly deactivate STAT3, therefore, treating cancers. To demonstrate the hypothesis, two series of novel resveratrol-caffeic acid hybrids were designed aiming to regulate both acetylation and phosphorylation of STAT3 protein, which is also the first report of the synthetic inhibitors simultaneously regulating two biological reactions of STAT3 to our knowledge. Most of these compounds were demonstrated with preferential antitumor activity with low IC 50 values against two cancer cell lines. Particularly, compound 7d was found as an excellent STAT3 inhibitor with over 50-fold better potency than resveratrol and caffeic acid. Meanwhile, the novel derivatives significantly inhibited the proliferation and induced the apoptosis of tumor cells. Molecular docking further disclosed the binding modes of STAT3 with the inhibitors. In addition, compound 7d orally and significantly suppressed breast cancer 4T1 xenograft tumor growth in vivo , indicating its great potential as an efficacious drug candidate for human cancer therapy. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
02235234
Volume :
124
Database :
Academic Search Index
Journal :
European Journal of Medicinal Chemistry
Publication Type :
Academic Journal
Accession number :
119220328
Full Text :
https://doi.org/10.1016/j.ejmech.2016.10.028